Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
3,367,000
-
Total 13F shares
-
1,072,275
-
Share change
-
+76,835
-
Total reported value
-
$3,658,805
-
Price per share
-
$3.42
-
Number of holders
-
17
-
Value change
-
+$244,093
-
Number of buys
-
5
-
Number of sells
-
6
Institutional Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q3 2023
As of 30 Sep 2023,
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,072,275 shares.
The largest 10 holders included
Slate Path Capital LP, MFN Partners Management, LP, FMR LLC, TYNDALL CAPITAL PARTNERS L P, Artal Group S.A., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., ACADIAN ASSET MANAGEMENT LLC, and Royal Bank of Canada.
This page lists
17
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.